Sonoma Pharmaceuticals (NASDAQ:SNOA) Issues Earnings Results

Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its quarterly earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.21, FiscalAI reports. Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.The company had revenue of $6.41 million during the quarter, compared to analyst estimates of $4.99 million.

Sonoma Pharmaceuticals Trading Up 10.6%

NASDAQ:SNOA traded up $0.12 during mid-day trading on Thursday, reaching $1.25. 1,508,925 shares of the stock were exchanged, compared to its average volume of 51,039. The business has a fifty day moving average price of $1.17 and a 200 day moving average price of $1.89. Sonoma Pharmaceuticals has a 1-year low of $0.85 and a 1-year high of $6.92. The firm has a market capitalization of $5.99 million, a PE ratio of -0.66 and a beta of 1.28.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a report on Friday, July 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

A hedge fund recently raised its position in Sonoma Pharmaceuticals stock. DRW Securities LLC increased its holdings in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the quarter. DRW Securities LLC owned 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.